OUR EXPERT NETWORK

• Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics

  Emerging therapies are being designed to safely deliver oligonucleotides to disease-relevant tissues. Delivery is no longer a technical hurdle to overcome but a strategic lever.

• Drugging The tRNA Control System

  Drug discovery has usually treated transfer RNA as cellular infrastructure: indispensable, highly conserved, and therefore dangerous to perturb. That description is accurate but incomplete. 

• Analytical Platforms: The Foundation Of The Next Generation Of RNA Therapeutics

  RNA therapeutics are entering a new era where analytical platforms drive scalability, regulatory confidence, manufacturing flexibility, and the development of increasingly complex products.

• A New Purification Strategy For The Removal Of dsRNA Impurities From IVT mRNA Products

  NIST research introduces a gentle SEC method that separates dsRNA impurities from IVT mRNA by tweaking buffer pH, achieving 81.8% target recovery without transcript damage.

• The Second Holy Grail Of Gene Editing: Large Knock-Ins

  Exploring the race to achieve large gene knock-ins, emerging editing platforms, and how overcoming this challenge could unlock therapies for many inherited diseases.